Indicative Announcement on ""Brightgene Convertible Bonds"" Expected to Meet Conditions for Redemption
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Indicative Announcement on ""Brightgene Convertible Bonds"" Expected to Meet Conditions for Redemption
Filed with SSE · · 4 pages · Chinese
Release
BrightGene Bio-Medical Technology Co. Ltd. on 6ix
Earlier from BrightGene Bio-Medical Technology
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Adding Provisional Proposal at 2025 Annual General Meeting
- Announcement on Resignation of the Directors and Senior Management Members
- BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States
- Announcement on Convening the 2025 Annual Performance Briefing
Later from BrightGene Bio-Medical Technology
- Announcement on Redeeming "BrightGene Convertible Bonds" in Advance
- Report for Q1 2026
- BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints
- 19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities
- Announcement on Redemption and Delisting of "BrightGene Convertible Bonds"
Follow BrightGene Bio-Medical Technology into a list and get an email when it puts out news.
Follow BrightGene Bio-Medical Technology